EryDel S.p.A. Revenue and Competitors
Estimated Revenue & Valuation
- EryDel S.p.A.'s estimated annual revenue is currently $4M per year.
- EryDel S.p.A.'s estimated revenue per employee is $155,000
Employee Data
- EryDel S.p.A. has 26 Employees.
- EryDel S.p.A. grew their employee count by -10% last year.
EryDel S.p.A.'s People
| Name | Title | Email/Phone |
|---|
EryDel S.p.A. Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is EryDel S.p.A.?
EryDel is a multi-asset, clinical stage biopharmaceutical company headquartered in Bresso (Milan), Italy dedicated to developing and commercializing novel treatments for rare diseases with high unmet need. In 2018 EryDel received the “Most Innovative StartUp Italia Award†chosen from startups across all industries. EryDel specializes in the delivery of drugs using the patient's own red blood cells. The lead product candidate, EryDex, is currently in Phase III development for the treatment of Ataxia Telangiectasia (AT), a rare neurological disorder for which no established therapy is currently available. EryDex received Orphan Drug designation for the treatment of AT both from FDA and EMA
keywords:N/A
N/A
Total Funding
26
Number of Employees
$4M
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
EryDel S.p.A. News
EryDel SpA: Italy's EryDel is presenting late-stage data from its Phase III ATTeST trial in Ataxia Telangiectasia at the American Academy of...
Other Companies in Bresso
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.3M | 28 | 8% | N/A |
#2 | $6.7M | 31 | 3% | N/A |
#3 | N/A | 92 | 8% | N/A |